Ignite Creation Date:
2024-05-06 @ 9:43 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03056755
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-20
First Post:
2017-02-15
Brief Title:
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutant HR HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-08-14
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-07-17
Completion Date Type:
ESTIMATED
First Submit Date:
2017-02-15
First Submit QC Date:
February 15 2017
Study First Post Date:
2017-02-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2024-03-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2022-05-13
Disp First Submit QC Date:
May 13 2022
Disp First Post Date:
2022-05-16
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-10-11
Last Update Post Date:
2024-06-20
Last Update Post Date Type:
ACTUAL